Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial

Table 2 Patients’ demographic data

Patient no.	Age (years)	Sex	Habit of betel quid chewing, cigarette smoking and alcohol consumption	Primary tumor site	Previous lines of treatment^a	Recurrence type	Cisplatin refractory	Cetuximab exposure	Treatment schedule	Best response	PFS (months)
1	47	Male	Yes	Buccal cavity	3	local	Yes	Yes	R then CT	SD	6.3
2	38	Male	Yes	Buccal cavity	3	local	Yes	Yes	R then CT	PD	1.9
3	49	Male	Yes	Hypopharynx	3	local	Yes	Yes	R then CT	PD	1.1
4	49	Male	Yes	Hypopharynx	3	Local +distant	Yes	Yes	R then CT	PD	1.9
5	39	Male	Yes	Tongue	2	Local (persistent)	Yes	No	R plus CT	PR	7.0
6	58	Male	Yes	Hypopharynx	2	Distant	Yes	Yes	R plus CT	CR	6.2
7	61	Male	Yes	Hypopharynx	1	Distant (persistent)	Yes	No	R plus CT	PD	1.6
8	33	Male	Yes	Tongue	3	Local	Yes	Yes	R plus CT	PD	0.7
9	48	Male	Yes	Oropharynx	2	Distant	Yes	Yes	R plus CT	PR	7.1
10	45	Male	Yes	Oropharynx	2	Local	Yes	No	R plus CT	SD	3.0

PFS progression-free survival, R rituximab, CT chemotherapy, SD stable disease, PD progressive disease PR partial response, CR complete response
^a including definitive treatment for locally advanced diseases

ISSN: 1471-2407